Preoperative Oral Magnesium to Prevent Postoperative Atrial Fibrillation Following Coronary Surgery (POMAF-CS)

• Status: Completed
• Trial end date: 2019-10-20
• Target enrollment: 0
• Participant gender: All

Summary

Post operative atrial fibrillation following coronary surgery (POAF) is a common complication that can affect 10-50% of patients.

Intravenous magnesium, administered per-or post-operatively, reduces the incidence of POAF. However, the effect of preoperative magnesium loading on the incidence of POAF is not yet studied.

200 patients admitted for elective coronary surgery under Cardiopulmonary bypass will be included in this prospective randomized controlled trial.

Treatment group will receive preoperative oral magnesium and control group will receive placebo for 3 days before the planned coronary artery surgery.

The occurrence of POAF will be studied as a main outcome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St Joseph University, Beirut, Lebanon
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Adult patients

• Coronary artery disease

• Planned coronary artery surgery

• signed informed consent

Exclusion Criteria:

• Preoperative supraventricular dysrhythmia including atrial fibrillation, either acute or chronic

• Left ventricular EF < 30%

• Urgent surgery

• Redo surgery

• Permanent preoperative pacemaker

• Preoperative anti arrythmia drugs classes I and III

• Post operative inotrope drugs

• Postoperative bradycardia necessitating electrosystolic pacing

• Preoperative heart rate less than 50 bpm

• documented preoperative dysthryroidism

• 2nd and 3rd degree atrioventricular bloc

• Renal failure with GFR < 30 ml/min/1.73 m²